Cancer – STRIvE-01: Phase I Study of EGFR806 CAR T Cell Immunotherapy for Relapsed or Refractory Solid Tumors in Children and Young Adults
Condition or Therapy:
What is the goal of this study?
A Food and Drug Administration-authorized clinical trial at Seattle Children’s is testing CAR T-cell therapy in children and young adults with relapsed or refractory solid tumors who are not likely to survive with standard treatments. The trial is called STRIvE-01.
Through this phase 1 trial, researchers are working to answer these questions:
- Is T-cell therapy safe to give to children and young adults with relapsed or refractory solid tumors?
- What is the best dose of CAR T cells for children and young adults with solid tumors?
- Does T-cell therapy work against solid tumors?
Who can join the study?
This trial is for children and young adults who:
- Have relapsed or refractory solid tumors that express the protein EGFR
- Are ages 1 to 26 years old
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
What will happen if my child takes part in this study?
In this trial, the patient’s own T cells are reprogrammed to recognize and target the protein EGFR, which is expressed by many childhood solid tumors, including sarcomas, kidney tumors, rhabdomyosarcoma, osteosarcoma and neuroblastoma.
You can read about the STRIvE-01 study protocol on clinicaltrials.gov.
Who can I contact for more information?
For more information, call 206-987-2106 or send us an email.